- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06391736
후기 발병 폼페병 유전자치료제의 안전성 및 유효성 평가
후기 발병 폼페병 환자에서 인간 산성 알파-글루코시다제(GAA) 이식유전자 정맥 주사를 발현하는 아데노 관련 바이러스 벡터의 안전성, 내약성 및 효능을 평가하기 위한 다기관, 단일군, 공개 라벨 연구
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: GeneCradle, Inc China
- 전화번호: 86-13501380583
- 이메일: ind@bj-genecradle.com
연구 장소
-
-
-
Beijing, 중국, 100853
- 모병
- Chinese PLA General Hospital
-
수석 연구원:
- Guang Yang
-
연락하다:
- Xinting Liu
- 전화번호: 16601558283
- 이메일: lxting0531@163.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 6 years, males or females;
- Patient has a diagnosis of LOPD;
- Patient has upright FVC ≥ 30% of predicted normal value;
- A 6MWT ≥ 40 meters, assistive device allowed;
- The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion Criteria:
- Patient who has any history or concurrent clinical organic disease, including cardiovascular and liver diseases, respiratory system, nervous system disease, or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
- Patient who requires invasive mechanical ventilation, or rely on noninvasive non-non-invasive assisted ventilation when sitting upright;
- Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
- Patient with a history of glucocorticoid allergy;
- Patient who has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug;
- Patient who has AAV9 neutralizing antibody titer ≥ 1:100;
- Patient who has participated in a previous gene therapy research trial;
- Pregnant or lactating female participants;
- Patients who have fertility plans within 6 months from screening to the end of the study and are unwilling to take effective physical contraceptive measures (such as a condom, intrauterine device, contraceptive ring, ligation, abstinence, etc.) for contraception (including the subject's partner);
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low dosage group
Single intravenous administration of GC301 at a dose of 3.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
|
실험적: High dosage group
Single intravenous administration of GC301 at a dose of 6.0 x 10^13 vector genomes per kilogram body weight |
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
프로토콜별 이상반응에 따른 용량 제한 독성(DLT) 비율(1상)
기간: 치료 후 30일 이내
|
치료 후 30일 이내
|
|
|
Number of Participants With Adverse Events
기간: 52 weeks
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
52 weeks
|
|
Percent Predicted Upright Forced Vital Capacity (FVC)(Phase 2)
기간: 52 weeks
|
Change from baseline in percentage of predicted FVC measured by pulmonary function testing |
52 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AAV 캡시드 및 GAA 도입유전자에 대한 면역반응 발생
기간: 52주
|
52주
|
|
|
6-Minute Walk Test
기간: 52 weeks
|
Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes |
52 weeks
|
|
Maximum Inspiratory Pressure (MIP)
기간: 52 weeks
|
Change from baseline in MIP measured by pulmonary function testing |
52 weeks
|
|
Maximum Expiratory Pressure (MEP)
기간: 52 weeks
|
Change from baseline in MEP measured by pulmonary function testing |
52 weeks
|
|
Muscle Status Testing - Quick Motor Function Test (QMFT) Measure
기간: 52 weeks
|
Measurement of functional motor abilities using the Quick Motor Function Test (QMFT) will be performed and the results compared with baseline. |
52 weeks
|
|
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
기간: 52 weeks
|
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life. |
52 weeks
|
|
Time needed for non-invasive ventilatory support
기간: 52 weeks
|
Change from baseline in time duration that needed for non-invasive ventilatory support |
52 weeks
|
|
The viral load of adeno-associated virus (AAV) vector
기간: 52 weeks
|
To assess the change of AAV vector copy numbers within 52 weeks after administration. |
52 weeks
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
GAA enzymatic activity
기간: 52 weeks
|
Change from baseline in GAA enzymatic activity in muscle biopsies |
52 weeks
|
|
GAA enzymatic activity
기간: 52 weeks
|
Change from baseline in GAA enzymatic activity in blood |
52 weeks
|
|
Glycogen content in muscle
기간: 52 weeks
|
Change from baseline in glycogen content in muscle biopsies |
52 weeks
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 의자: Guang Yang, Chinese PLA General Hospital
- 수석 연구원: Guang Yang, Chinese PLA General Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- JLJY-GC301-LOPD-001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .